公开(公告)号：US20110020360A1

公开(公告)日：2011-01-27

申请号：US12708022

申请日：2010-02-18

申请人： NAOMI LAING ,  JASPAL SINGH KANG ,  IAN FOLTZ ,  GADI GAZIT-BOMSTEIN ,  XIAO-DANG YANG ,  SUE A. CARTLIDGE ,  DAVID CHARLES BLAKEY

发明人： NAOMI LAING ,  JASPAL SINGH KANG ,  IAN FOLTZ ,  GADI GAZIT-BOMSTEIN ,  XIAO-DANG YANG ,  SUE A. CARTLIDGE ,  DAVID CHARLES BLAKEY

IPC分类号： A61K39/395 ,  C07K16/00 ,  C07H21/04 ,  C12N15/63 ,  A61P35/00 ,  A61K39/44 ,  C12N5/10

CPC分类号： C07K16/2863 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

摘要： Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.

摘要翻译： 本文公开了针对抗原PDGFR-α的靶向结合剂及其用途。 更具体地，本发明涉及针对抗原PDGFR-α的完全人单克隆抗体以及这些抗体的用途。 本发明的方面还涉及表达这种抗体的杂交瘤或其它细胞系。 所描述的靶向结合剂和抗体可用作诊断和治疗与PDGFR-α的活性和/或过度表达相关的疾病。

公开(公告)号：US07754859B2

公开(公告)日：2010-07-13

申请号：US11833473

申请日：2007-08-03

申请人： Naomi Laing ,  Jaspal Singh Kang ,  Ian Foltz ,  Gadi Gazit-Bornstein ,  Xiao-Dang Yang ,  David Charles Blakey ,  Sue A. Cartlidge

发明人： Naomi Laing ,  Jaspal Singh Kang ,  Ian Foltz ,  Gadi Gazit-Bornstein ,  Xiao-Dang Yang ,  David Charles Blakey ,  Sue A. Cartlidge

IPC分类号： C12P21/08 ,  C07K16/00 ,  A61K39/00 ,  C07K17/00 ,  C07K17/14

CPC分类号： C07K16/2863 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

摘要： Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.

摘要翻译： 本文公开了针对抗原PDGFR-α的靶向结合剂及其用途。 更具体地，本发明涉及针对抗原PDGFR-α的完全人单克隆抗体以及这些抗体的用途。 本发明的方面还涉及表达这种抗体的杂交瘤或其它细胞系。 所描述的靶向结合剂和抗体可用作诊断和治疗与PDGFR-α的活性和/或过度表达相关的疾病。

公开(公告)号：US08697664B2

公开(公告)日：2014-04-15

申请号：US12708022

申请日：2010-02-18

申请人： Naomi Laing ,  Jaspal Singh Kang ,  Ian Foltz ,  Gadi Gazit-Bornstein ,  Xiao-Dang Yang ,  Sue A. Cartlidge ,  David Charles Blakey

发明人： Naomi Laing ,  Jaspal Singh Kang ,  Ian Foltz ,  Gadi Gazit-Bornstein ,  Xiao-Dang Yang ,  Sue A. Cartlidge ,  David Charles Blakey

IPC分类号： C12N15/13 ,  C12N5/10 ,  C07H21/04 ,  A61K31/70

CPC分类号： C07K16/2863 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

摘要： Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.

摘要翻译： 本文公开了针对抗原PDGFR-α的靶向结合剂及其用途。 更具体地，本发明涉及针对抗原PDGFR-α的完全人单克隆抗体以及这些抗体的用途。 本发明的方面还涉及表达这种抗体的杂交瘤或其它细胞系。 所描述的靶向结合剂和抗体可用作诊断和治疗与PDGFR-α的活性和/或过度表达相关的疾病。